Diabetes and cardiovascular disease interventions by community pharmacists: A systematic review;Une Revue Systématique des Interventions des Pharmaciens dans la Prise en Charge du Diabéte et des Maladies Cardiovasculaires

Annals of Pharmacotherapy

Volumn 45, Issue 5, 2011, Pages 615-628

  Evans, Charity D ^a   Watson, Erin ^a   Eurich, Dean T ^b   Taylor, Jeff G ^a   Yakiwchuk, Erin M ^a   Shevchuk, Yvonne M ^a   Remillard, Alfred ^a   Blackburn, David ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiovascular disease; Community pharmacy; Diabetes; Intervention

Indexed keywords

HEMOGLOBIN A1C;

ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INTERVENTION STUDY; PHARMACIST; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; COMMUNITY PHARMACY SERVICES; DIABETES MELLITUS; HUMANS; PHARMACIES; PROFESSIONAL ROLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 79957601938     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P615     Document Type: Article

References (74)

1. Tsuyuki R, Semchuk W, Poirier L. 2006 Canadian Hypertension Education Program guidelines for the management of hypertension by pharmacists. Can Pharm J 2006;139(suppl 1):511-3.
2. Romanow R. Building on values: the future of health care in Canada-final report. Ottawa: Government of Canada, 2002.
3. Department of Health. Choosing health through pharmacy-a programme for pharmaceutical public health 2005-2015. London: Department of Health, 2005.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97. DOI 10.1001/jama.285.19.2486
5. Machado M, Bajcar J, Guzzo G, Einarson T. Sensitivity of patient outcomes to pharmacist intervention. Part II: systematic review and metaanalysis in hypertension management. Ann Pharmacother 2007;41: 1770-81. DOI 10.1345/aph.1K311
6. Pearson G, Thompson A, Semchuk W. Guidelines for the management of dyslipidemias and prevention of cardiovascular disease by pharmacists. Can Pharm J 2008;141(suppl 2):S11-6.
7. O'Loughlin J, Masson P, Dery V, Fagnan D. The role of community pharmacists in health education and disease prevention: a survey of their interests and needs in relation to cardiovascular disease. Preventive Medicine 1999;28:324-31.
8. Charrois TL, Durec T, Tsuyuki RT. Systematic reviews of pharmacy practice research: methodologic issues in searching, evaluating, interpreting, and disseminating results. Ann Pharmacother. 2009;43:118-22. DOI 10.1345/aph.1L302
9. Wubben D, Vivian E. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy 2008;28:421-36. DOI 10.1592/phco.28.4.421
10. Machado M, Nassor N, Bajcar JM, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother 2008;42:1195-207. DOI 10.1345/aph.1K618
11. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother 2007;41: 1569-82. DOI 10.1345/aph.1K151
12. Blenkinsopp A, Hassey A. Effectiveness and acceptability of community pharmacy-based interventions in type 2 diabetes: a critical review of intervention design, pharmacist and patient perspectives. Int J Pharm Pract 2005;13:231-40.
13. Cross L, Franks A. Clinical outcomes associated with pharmacist involvement in patients with dylipidemia. Dis Manage Health Outcomes 2005;13:31-42.
14. Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health Med 2003;25:144-53.
15. Downs S, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun Health 1998;52:377-84. DOI 10.1136/jech.52.6.377
16. Concato J, Shah N, Horwitz R. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342:1887-92.
17. Malcomson K, Dunwoody L, Lowe-Strong A. Psychosocial interventions in people with multiple sclerosis. J Neurol 2007;254:1-13.
18. Paulos CP, Akesson Nygren CE, Celedon C, Carcamo CA. Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia. Ann Pharmacother 2005;39:939-43. DOI 10.1345/aph.1E347
19. Park J, Kelly P, Carter B, Burgess P. Comprehensive pharmaceutical care in the chain setting. J Am Pharm Assoc 1996;NS36:443-51.
20. Donner A. Sample size estimation for cluster randomization designs. In: Donner A, Klar N, eds. Design and analysis of cluster randomization trials in health research. New York: Oxford University Press Inc., 2000:52-78.
21. Donner A, Klar N. Pitfalls of and controversies in cluster randomization trials. Am J Public Health 2004;94:416-22.
22. Doucette WR, Witry MJ, Farris KB, McDonough RP. Community pharmacist-provided extended diabetes care. Ann Pharmacother 2009; 43:882-9. DOI 10.1345/aph.1L605
23. Fera T, Bluml B, Ellis W, Schaller C, Garrett D. The Diabetes ten city challenge: interim clinical and humanistic outcomes of a multisite community pharmacy diabetes care program. J Am Pharm Assoc 2008;48: 181-90.
24. Krass I, Armour C, Mitchell B, et al. The pharmacy diabetes care program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med 2007;24:677-83.
25. Fornos J, Andres NF, Andres JC, Guerra M, Egea B. A pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain. Pharm World Sci 2006;28:65-72.
26. Krass I, Taylor SJ, McInman AD, Armour CL. The pharmacist's role in continuity of care in type 2 diabetes: an evaluation of a model. J Pharm Technol. 2006;22:3-8.
27. Garrett D, Bluml B. Patient self-management program for diabetes: firstyear clinical, humanistic, and economic outcomes. J Am Pharm Assoc 2005;45:130-7.
28. Taylor S, Milanova T, Hourihan F, Krass I, Coleman C, Armour C. A cost-effectiveness analysis of a community pharmacist-initiated disease state management service for type 2 diabetes mellitus. Int J Pharm Pract 2005;13:33-40.
29. Cranor C, Bunting B, Christensen D. The Asheville project: long-term clinical and economical outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:173-84.
30. Cranor C, Christensen D. The Asheville project: short term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:149-59.
31. Nau D, Ponte C. Effects of a community pharmacist-based diabetes patient-management program on intermediate clinical outcome measures. J Managed Care Pharm 2002;8:48-53.
32. Berringer R, Shibley M, Cary C, Pugh C, Powers P, Rafi J. Outcomes of a community pharmacy-based diabetes monitoring program. J Am Pharm Assoc 1999;39:791-7.
33. Fincham J, Lofholm P. Saving money and lives: pharmacist care for diabetes patients. America's Pharmacist 1998;Mar:49-52.
34. Turnacilar M, Sancar M, Apikoglu-Rabus S, Hursitolglu M, Izzettin FV. Improvement of diabetes indices of care by a short pharmaceutical care program. Pharm World Sci 2009;31:689-95. DOI 10.1007/s11096-009-9333-9
35. Planas L, Crosby K, Mitchell K, Farmer K. Evaluation of a hypertension medication therapy management program in patients with diabetes. J Am Pharm Assoc 2009;49:164-70.
36. Lai L. Community pharmacy-based hypertension disease-management program in a Latino/Hispanic-American population. Consultant Pharm 2007;22:411-6.
37. Oparah A, Adje D, Enato E. Outcomes of pharmaceutical care intervention to hypertensive patients in a Nigerian community pharmacy. Int J Pharm Pract 2006;14:115-22.
38. Zillich A, Sutherland J, Kumbera P, Carter B. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study). J Gen Intern Med 2005;20:1091-16. DOI 10.1111/j.1525-1497.2005.0226.x
39. Chabot I, Moisan J, Gregoire J, Milot A. Pharmacist intervention program for control of hypertension. Ann Pharmacother. 2003;37:1186-93. DOI 10.1345/aph.1C267
40. Garcao J, Cabrita J. Evaluation of a pharmaceutical care program for hypertensive patients in rural Portugal. J Am Pharm Assoc 2002;42:858-64.
41. Blenkinsopp A, Phelan M, Bourne J, Dakhik N. Extended adherence support by community pharmacists for patients with hypertension: a randomized controlled trial. Int J Pharm Pract 2000;8:165-75.
42. Robinson JD, Segal R, Lopez LM, Doty RE. Impact of a pharmaceutical care intervention on blood pressure control in a chain pharmacy practice. Ann Pharmacother 2010;44:88-96. DOI 10.1345/aph.1L289
43. Nietert P, Tilley B, Zhao W, et al. Two pharmacy interventions to improve refill persistence for chronic disease medications: a randomized, controlled trial. Med Care 2009;47:32-40. DOI 10.1097/MLR.0b013e3181808c17
44. Vrijens B, Vincze G, Kristano P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114-7. DOI 10.1136/bmj.39553.670231.25.
45. Ali F, Laurin M-Y, Lariviere C, Tremblay D, Cloutier D. The effect of pharmacist intervention and patient education on lipid lowering medication compliance and plasma cholesterol levels. Can J Clin Pharmacol 2003;10:101-6.
46. Bouvy M, Heerdink E, Urquart J, Grobbee D, Hoe A, Leufkens H. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study. J Card Failure 2003;9:404-11.
47. Taylor S, Frazier M, Shimp L, Boyd E. Implementing pharmaceutical care in an inner city pharmacy: hypertension management and elderly African Americans. J Aging Pharmcother 2003;13:63-77.
48. Skaer T, Sclar D, Markowski D, Won J. Effect of value-added utilities on prescription refill compliance and Medicaid health care expenditures-a study of patients with non-insulin-dependent diabetes mellitus. J Clin Pharm Ther 1993;18:295-9.
49. Ascione F, Brown G, Kirking D. Evaluation of a medication refill reminder system for a community pharmacy. Patient Educ Counsel 1985; 7:157-65.
50. McKenney J, Brown J, Necsary R, Reavis L. Effect of pharmacist drug monitoring and patient education on hypertensive patients. Cont Pharm Practice 1978;1:50-6.
51. Eussen SRBM, van der Elst ME, Klungel OH, et al. A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial. Ann Pharmacother 2010;44:1905-13. DOI 10.1345/aph.1P281
52. Tsuyuki R, Olson K, Dubyk A, Schindel T, Johnson J. Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). Am J Med 2004;116:130-3.
53. Yamada C, Johnson J, Robertson P, Pearson G, Tsuyuki R. Long-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: extended follow-up of the second study of cardiovascular risk intervention by pharmacists (SCRIPplus). Pharmacotherapy 2005;25:110-5. DOI 10.1592/phco.25.1.110.55619
54. The Community Pharmacy Medicines Management Project Evaluation team. The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Fam Pract 2007;24:189-200. DOI 10.1093/fampra/cml075
55. Semchuk W, Taylor J, Sulz L. Pharmacist intervention in risk reduction study: high-risk cardiac patients. Can Pharm J 2007;140:32-7.
56. Tsuyuki R, Johnson J, Teo K, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med 2002;162:1149-55.
57. Bluml B, McKenney J, Cziraky M. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc 2000;40: 157-65.
58. Shibley MC, Pugh CB. Implementation of pharmaceutical care services for patients with hyperlipidemias by independent community pharmacy practitioners. Ann Pharmacother 1997;31:713-9.
59. Ibrahim OM, Catania PN, Mergener MA, Supernaw RB. Outcome of cholesterol screening in a community pharmacy. DICP Ann Pharmacother 1990;24:817-21.
60. Nola KM, Gourley D, Portner T, et al. Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting. J Am Pharm Assoc 2000;40:166-73.
61. Krass I, Hourihan F, Chen T. Health promotion and screening for cardiovascular risk factors in NSW: a community pharmacy model. Health Promotion J Aust 2003;14:101-7.
62. Van Wijk BLG, Klungel OH, Heerdink ER, de Boer A. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Ann Pharmacother 2005;39: 319-28. DOI 10.1345/aph.1E027
63. Morrison A, Wertheimer A. Evaluation of studies investigating the effectiveness of pharmacists' clinical services. Am J Health-Syst Pharm 2001; 58:569-77.
64. Kennie NR, Schuster BG, Einarson TR. Critical analysis of the pharmaceutical care research literature. Ann Pharmacother 1998;32:17-26.
65. Gordis L. Assessing the efficacy of preventative and therapeutic measures: randomized trials. In: Merritt J, Hall A, eds. Epidemiology. 4th ed. Philadelphia: Saunders Elsevier, 2004:133.
66. Moher D, Schulz K, Altman D. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;134:657-62.
67. von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4:e296. DOI 10.1371/journal.pmed.0040296
68. Hepler C, Strand L. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533-43.
69. Roughead E, Semple S, Vitry A. Pharmaceutical care services: a systematic review of pubished studies, 1990 to 2003, examining effectiveness in improving patient outcomes. Int J Pharm Pract 2005;13:53-70.
70. Simpson S, Johnson J, Biggs C, et al. Practice-based research: lessons from community pharmacist participants. Pharmacotherapy 2001;21: 731-9. DOI 10.1592/phco.21.7.731.34570
71. Farris K, Schopflocher D. Between intention and behaviour: an application of community pharmacists' assessment of pharmaceutical care. Soc Sci Med 1999;49:55-66.
72. Armour C, Brillant M, Krass I. Pharmacists' views on involvement in pharmacy practice research: strategies for facilitating participation. Pharm Pract 2007;5:59-66.
73. Saini B, Brillant M, Filipovska J, et al. Factors influencing Australian community pharmacists' willingness to participate in research projects-an exploratory study. Int J Pharm Pract 2006;14:179-88.
74. Harrison R, Siminoski K, Vethanayagam D, Majumdar S. Osteoporosisrelated kyphosis and impairments in pulmonary function: a systematic review. J Bone Miner Res 2007;22:447-57.